Dr. Olga Kubassova - Chief Executive Officer, Clinical Research Innovator
Dr. Kubassova is a mathematician passionate about innovative clinical research approaches, use of advanced imaging in clinical trials, use of technology to enable efficient delivery of trials, more efficient ways to prove safety and efficacy of novel compounds and commercial success of pharma & biotech companies. Olga’s ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IA scope and partnerships. She is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
Richard Barker, OBE - Chairman, Precision Medicine Expert
Prof. Barker' 25-year business career has spanned biopharmaceuticals, diagnostics and bioinformatics – both in the USA and EU, focused on accelerating the translation of therapeutics with the potential to improve healthy lifespan on a global scale. Richard is an expert in precision medicine, stratified medicine, translational partnerships between academia and industry. He headed the Association of the British Pharmaceutical Industry, currently on the boards of CelGene, New Medicine Partners, Centre for Advancing Sustainable Medical Innovation (CASMI), the UK government Precision Medicine Catapult and Honorary Fellow of the British Pharmacological Society.
Dr. Mikael Boesen, MD, PhD - Clinical Advisory Board, Musculoskeletal Imaging Expert
18+ years of musculoskeletal radiology and advancing clinical research in inflammatory and degenerative joint diseases. Dr. Boesen has 12+ years of hand-on experience in imaging protocol design, imaging study set-up, scoring and reporting in especially MSK diseases. He is a distinguished PI and an invited speaker in national and international symposiums. Mikael's special interest in advanced imaging of patients with various musculoskeletal conditions including rheumatoid arthritis, osteoarthritis and psoriatic arthritis, especially dealing with quantification of inflammation using Magnetic Resonance Imaging. Dr. Boesen is an Associate Professor at the Parker Institute, Head of MRI research and senior consultant in musculoskeletal radiology at department of Radiology Bispbjerg and Frederiksberg Hospitals, Denmark. He has authored of 80+ articles and book chapters.
Prof. Peter Taylor, MA, BM, BCh, FRCP, FRCPE - Clinical Advisory Board, Rheumatology Clinical Expert
Prof. Peter C. Taylor holds the Norman Collisson Chair of Musculoskeletal Sciences, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK. Prof. Taylor has specialist clinical interests in rheumatoid arthritis and early inflammatory arthritis. He has over 20 years' experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in RA and AS. His research interests are in the use of novel imaging for evaluation of prognosis, the assessment of responses to therapy and as an early indicator of inflammation suppression as well as disease modification particularly as applied to early phase clinical trial design. He pioneered studies using such measures as primary outcome measures in early phase Ib/IIa studies with a view to informing later phase study design. He has been a principal investigator in numerous international clinical trials of biologic therapies including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy and is currently chief investigator in a number of small molecule therapies in clinical trials for rheumatoid arthritis and ankylosing spondylitis.
Dr. Sotirios Bisdas, MD, PhD, MSc - Clinical Advisory Board, Advanced Oncology Expert
Prof. Sotirios Bisdas, Neuroradiologist, Senior Lecturer (Institute of Neurology, UCL), Professor in Radiology (University of Tübingen, Germany), MSc in Advanced Oncology (University of Ulm, Germany). PI in cutting-edge MRI and PET research in brain tumours. 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. Involved in guidelines for the use of perfusion imaging in Oncology.
Prof. Hani Gabra - Clinical Advisory Board, Clinical Oncology Expert
Dr. Gabra is Professor of Medical Oncology and Deputy Head of the Division of Cancer (Clinical). He is Head of the Molecular Therapeutics Unit and Director of the Ovarian Cancer Action Research Centre at Imperial College, London, UK. Within Imperial College Healthcare NHS Trust he is Head of Medical Oncology, Chair of the Cancer Research Committee and is Honorary Consultant Medical Oncologist. He is also Associate Director and Lead of the Cancer Division of the NIHR Clinical Research Network for North West London. His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors. Hani's research is principally funded by Ovarian Cancer Action, the national ovarian cancer charity. He is also funded by CRUK and EU FP7 as well as translational / clinical trials funding from pharmaceutical collaborations.
Dr. Diana Roettger, PhD - Imaging in Clinical Research Expert
10+ years of scientific expertise in medical imaging and advising life science companies on how to use imaging biomarkers to accelerate their drug development and ensure better ROIs from their clinical R&D programmes. With PhD in computational neuro-imaging and in-depth imaging expertise in clinical trial design, regulatory pathways and biomarkers, Dr. Roettger works with our clients to ensure successful planning and execution of clinical trial programmes in solid tumours, immuno-oncology, inflammation, rare & orphan diseases.
Jeppe Ragnar Andersen - NED, Global Clinical Research and Investments in Osteoarthritis
Jeppe Ragnar Andersen is CEO of Nordic Bioscience, Denmark. Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes. Jeppe brings operational expertise of running global multi-center clinical trials in MSK conditions.
Prof. Henning Bliddal, MD, DMSc - Clinical Advisory Board, Clinical Osteoarthritis Expert
Henning Bliddal is a Director and research professor at the Parker Institute, Denmark. Since 2005, Prof. Bliddal has been the chairman of The Danish National Board of Health’s commission for treatment of knee osteoarthritis. Co-author of 150+ peer-reviewed articles and a renowned architect of numerous research projects. His clinical research aims at increasing the knowledge of treatments for the major groups of diseases, including degenerative musculoskeletal diseases such as osteoarthritis, immuno-inflammatory diseases of joints, especially rheumatoid arthritis, soft tissue pain conditions; furthermore, the Parker Institute has an international status for diagnosis of sequels of torture.
Dr. Guillermo Valenzuela, M.D., F.A.C.R., Rheumatologist - Clinical Advisory Board, Clinical Rheumatology Expert
Dr. Valenzuela is a MD with degrees from the University of Buenos Aires, New York Medical College, Cornell University Medical College is a practising rheumatologist running one of the largest state-of-the-art practices located in Plantation, Florida, USA. He has been continually contributing to the development of new treatments by actively participating in clinical studies. Dr Valenzuela is a recognized leader in the treatment of complex cases of Arthritic and Rheumatic diseases and specializes in Rheumatoid Arthritis, Osteoporosis, Carpal tunnel, Lupus (SLE), Gout, Sjogrens syndrome, Spondylitis Ankylosing.
Prof. Mikkel Østergaard, MD, PhD, DMSc - Clinical Advisory Board, Imaging in Rheumatoid Arthritis Expert
With special interest in MRI and US of joints affected by rheumatoid arthritis, Prof. Mikkel Østergaard co-authored more than 125 scientific articles on rheumatoid arthritis and other inflammatory arthritides and has been involved in national and international clinical and imaging studies.
Dr. Nikolay Tzaribachev, MD - Clinical Advisory Board, Paediatric Rheumatology Expert
Dr. Tzaribachev is a passionate advocate and a clinical researcher dedicated to the development of better treatment for children suffering from juvenile joint disease. Dr. Tzaribachev is running one of the largest clinics and is a hands-on paediatric rheumatologist at the University Children’s Hospital in Tuebingen, Germany. With over 20 years of experience in treating juvenile RA, JIA and other paediatric joint disease, he has been a consultant to major pharmaceutical companies, distinguished PI on global multi centre studies and co-authored over 100 papers advocating the use of imaging for better diagnosis and patient treatment. http://www.mdedge.com/familypracticenews/article/35069/rheumatology/mri-important-tool-identifying-silent-jia
Dr. John Carrino, MD, MPH - Clinical Advisory Board, Musculoskeletal Imaging Expert
Dr. Carrino is an internationally renowned radiologist with particular expertise in diagnostic imaging and percutaneous image-guided intervention. He is a co-author on over 200 peer reviewed publications in a variety of areas. His interests are in musculoskeletal diagnostic imaging (MRI, CT, Ultrasound, Radiography), image guided therapy (IGT), medical informatics, standards and health services research. Currently, he serves as a Vice Chairman, Department of Radiology and Imaging at Hospital for Special Surgery. NY, USA.
Catherine McClinton - Clinical Trials Operations Expert
Recognised as a results-driven and pragmatic project leader, expert in building solid professional and profitable working partnerships to achieve excellent outcomes while managing stakeholders expectations. Catherine brings 20 years of experience in setting up and operating clinical trial departments, running global multi-centre trials and managing distributed stakeholders. Her expertise is in delivery excellence, regulatory compliance, patient recruitment, clinical expertise, budget and contract management.
Mark Hinton, MBA - CTO, Large Scale Cloud Enterprise Software Expert
Mark is a pioneer and a global expert in building large scale cloud enterprise software for clinical research. His experience is in data logistics, optimization of clinical trials operations and use of technology to manage risk in clinical trials. His interests are in big data, use of machine learning and AI to optimise and de-risk execution of global trials.
Jeremy Nettle - NED, Digital Disruption on the Healthcare Expert
Jeremy has served as a Global Client Adviser for Healthcare in Oracle for 10 years and joint IA-group to provide our clients with deep strategic insight into the use of cloud based next generation systems and analytics in clinical practise. Jeremy is a global expert on the impact of digital disruption on the healthcare market and the NHS. His key role is in providing clinical, change management and technology expertise to the life sciences companies, focused on digital transformation solutions to meet the requirement of a changing and demanding and integrated health science market across the UK and Europe.
Robert Karl - NED, Investment Strategy and Capital for Life-Sciences Companies
A partner of RBV Capital, Robert joint IA-Group in 2015 to contribute to strategic growth of the group and expand IA-Capital Innovations. He is heavily involved into building a diversified investment portfolio composed of early to market stage products. His interests are in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, medical devices and innovative healthcare providers as well as cross-discipline companies.
Dr. Syed Rahman-Uddin - Clinical Assistant Professor of Radiology
Clinician, specializing in Cancer Radiology and the founder of 3D Oncologic Imaging Center at the City of Hope Comprehensive Cancer Center, USA. He has extensive knowledge in advanced oncology imaging and over 15 years of hands-on experience in CT, MR and US clinical research. His area of interest is the development and validation of imaging biomarkers in liver imaging, urologic tumor assessment, prostate imaging, angiography of renal and mesenteric arteries and peripheral runoff assessment, 3D virtual assessment of colon and colonography, lung assessment for nodule, cancer screening and surgical planning, cardio-vascular surgical planning, advanced imaging for detailed neurovascular exams for the assessment of aneurysm and stenosis measurement with curved reformatting. He is a widely published author, speaker and a member of several editorial boards.
Dr. Asim Mian - Assistant Professor of Radiology
Asim Mian, MD., Assistant Professor of Radiology at Boston University School of Medicine and co-founder of Boston Imaging Core Lab. He is a board certified radiologist with a certificate of added qualification in Neuroradiology. Dr. Mian completed his fellowship in Neuroradiology at Brigham and Women's Hospital, Harvard Medical School and his MD at University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School.
Dr Francesco Del Galdo - Clinical Advisory Board Member, Associate Professor, Head of Scleroderma Programme at the Leeds Institute of Rheumatic and Musculoskeletal Medicine
PhD studies and post doctoral Fellowship focused on early events in the pathogenesis of Scleroderma
5 years in the Scleroderma Center of Thomas Jefferson University in Philadelphia, USA
Pioneered application of Optical Coherence Tomography, MRI and serum biomarkers of overall fibrosis as outcome measures of activity and early diagnosis in Scleroderma.
Dr. Stephan Anderson - Professor of Radiology
Dr. Stephan Anderson (IA’s Clinical Advisory Board), diagnostic radiologist in Boston Medical Center, specializing in thoraco-abdominal imaging. Recent works and special interest are in renal imaging, bowel imaging, liver cancer, vascular injuries, vasculitis. Over 15 years of experience in reading and analyzing MRI, CT and metabolic images in clinical and research settings.
What Our Clients Say
I am a clinical-research fellow with high experience in prostate MRI analysis and reporting. I have been using Dynamika mostly to help the analysis support team to develop a PI-RADS structured reporting user interface.
The software is extremely useful and has the potential to be used in daily clinical practice. One of the most important skills of Dynamika is the capability of providing high quality tools to report prostate mpMRIs together with the possibility of assessing quantitative analysis at the same time.
Therefore, Dynamika opens a new window in the use of automated and semi-automated algorithms both for clinical and research purposes.
The integration of these two aspects is further strengthened by the remarkable competence of the support team that is constantly willing to help me when necessary.
I hope to keep on working with Dynamika and taking advantage of all its valuable tools during my clinical-research practice.
Francesco Giganti- Clinical Research Fellow, University College Hospital, London, UK
- Dynamika is really fantastic! Salvatore Costantino, Post Doctoral Researcher, University of Sassari, Italy
- I feel strongly that by making Dynamika available, student researchers could come up with very interesting and meaningful quantitative projects. Laura, Radiographer
- Dynamika is key to precise and accurate early diagnostics and a powerful tool for follow-up of post-op and post chemo and/or radio treatment patients. Roman Marin, Head of CT and MRI Department
- We have been using Dynamika software to analyse DCE data as part of a research project using multiparametric MRI for targeted radiotherapy treatment planning. We have found the software extremely useful compared with software delivered with our MRI scanner for a number of reasons, in particular: the ability to control each stage of the data processing, the ability to assess image quality and examine the parametric and pharmacokinetic maps in detail. Our project requires a quantitative (rather than qualitative) analysis of the DCE data and we have been very impressed with the collaborative approach of the Image Analysis support team in helping us achieve our goals. In addition, we commend the support team in providing informative and responsive training sessions and willingness to develop the software to meet the needs of our research project. Hayley Reynolds, Research Fellow, The Peter MacCullum Cancer Centre, Melbourne, Australia